Analytical Data
-
基因名
F8
- Application
-
别名
F8；SIAT8F；Alpha-2.8-sialyltransferase 8F
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P61647
-
表达区间
1-398aa
-
氨基酸序列
MRPGGALLALLASLLLLLLLRLLWCPADAPGRARILVEESREATHGTPAALRTLRSPATAVPRATNSTYLNEKSLQLTEKCKNLQYGIESFSNKTKGYSENDYLQIITDIQSCPWKRQAEEYANFRAKLASCCDAVQNFVVSQNNTPVGTNMSYEVESKKEIPIKKNIFHMFPVSQPFVDYPYNQCAVVGNGGILNKSLCGTEIDKSDFVFRCNLPPTTGDVSKDVGSKTNLVTINPSIITLKYGNLKEKKALFLEDIATYGDAFFLLPAFSFRANTGTSFKVYYTLEESKARQKVLFFHPKYLKDLALFWRTKGVTAYRLSTGLMITSVAVELCKNVKLYGFWPFSKTVEDIPVSHHYYDNKLPKHGFHQMPKEYSQILQLHMKGILKLQFSKCEVA
-
分子量
44.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
F8 recombinant protein, also known as recombinant Factor VIII, plays a crucial role in the treatment of hemophilia A, a genetic disorder characterized by the deficiency of clotting factor VIII, leading to excessive bleeding. Traditional treatments for hemophilia involved administering plasma-derived Factor VIII, which posed risks such as viral transmission and fluctuating factor levels. In the 1980s, advancements in biotechnology led to the development of recombinant Factor VIII, produced through genetic engineering techniques, allowing for a safer and more consistent supply. Research has focused on improving the stability, efficacy, and safety of F8 recombinant proteins, leading to the creation of various formulations with longer half-lives and reduced immunogenicity. These innovations have significantly enhanced the quality of life for hemophilia patients, reducing the frequency of infusions and complications associated with antibodies formed against Factor VIII. Ongoing studies aim to explore novel delivery methods, combination therapies, and gene therapy approaches to provide more effective and durable treatment solutions for individuals affected by hemophilia A.
